Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...

(Reuters) - Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, the ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Novartis announced that it has agreed to terms to acquire Anthos Therapeutics for an upfront payment of $925 million. The deal will include abelacimab, a Factor XI-inhibiting monoclonal antibody in ...

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for approximately $3.1bn. The deal gives Novartis access to abelacimab, which ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...

Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.

Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal For over 30 years, Congress has imposed price ceilings on prescription drugs ...

Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and ...